Osman El Jundi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Osman El Jundi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Hafize Uzun
Department of Biochemistry, Faculty of Medicine, Istanbul Atlas University, Istanbul 34408, Turkey
2 shared publications - Pelin Uysal
Department of Chest Diseases, Faculty of Medicine, Istanbul Atlas University, Istanbul 34403, Türkiye
2 shared publications - Aysen Kutan Fenercioglu
Department of Family Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, 34098 Istanbul, Turkey
1 shared publication - Gulenay Defne Ozen
Department of Psychology, McGill University, Montréal, QC H3A 1G1, Canada
1 shared publication - Naile Fevziye Misirlioglu
Department of Biochemistry, Faculty of Medicine, Istanbul Nişantaşı University, Istanbul 34398, Türkiye
1 shared publication - Oguzhan Cucu
Department of Anaesthesiology and Intensive Care, Medicana Zincirlikuyu Hospital, 34394 Istanbul, Turkey
1 shared publication
Latest Publications
- Open Access
Presepsin and Pentraxin-3 as Diagnostic and Severity Biomarkers in Community-Acquired Pneumonia: A Pilot Study
Background: Biomarkers reflecting innate immune activation may complement clinical severity scores in community-acquired pneumonia (CAP). This study evaluated serum presepsin and pentraxin-3 (PTX3) concentrations in patients with CAP and healthy controls and examined their associations with pneumonia severity. Methods: Ninety participants were analyzed, including 45 patients with CAP and 45 healthy controls. Pneumonia severity was assessed using the Pneumonia Severity Index (PSI) and CURB-65. Group comparisons, Spearman correlation analyses, receiver operating characteristic (ROC) analyses, and an exploratory multivariable logistic regression model were performed. Results: Presepsin concentrations were higher in patients with CAP than in healthy controls (2157 [1824–2524] vs. 1749 [1652–1879] pg/mL; p < 0.001), as were PTX3 concentrations (2.15 [1.76–2.87] vs. 1.67 [1.40–2.11] ng/mL; p < 0.001). For discrimination of CAP from healthy controls, the AUC was 0.822 (95% CI 0.728–0.902) for presepsin and 0.706 (95% CI 0.598–0.810) for PTX3. Among patients with CAP, presepsin correlated with PSI (rho = 0.552, p < 0.001) and CURB-65 (rho = 0.600, p < 0.001), while PTX3 showed stronger correlations with PSI (rho = 0.691, p < 0.001) and CURB-65 (rho = 0.668, p < 0.001). For identifying PSI classes IV–V, the AUC was 0.647 for presepsin and 0.742 for PTX3. Conclusions: Both presepsin and PTX3 were elevated in CAP and were associated with increasing disease severity. Within this pilot sample, presepsin showed a numerically higher AUC for discrimination between CAP and healthy controls, whereas PTX3 showed stronger associations with severity. Larger prospective studies are required to validate these findings.
Open AccessPresepsin and Pentraxin-3 as Diagnostic and Severity Biomarkers in Community-Acquired Pneumonia: A Pilot Study
Background: Biomarkers reflecting innate immune activation may complement clinical severity scores in community-acquired pneumonia (CAP). This study evaluated serum presepsin and pentraxin-3 (PTX3) concentrations in patients with CAP and healthy controls and examined their associations with pneumonia severity. Methods: Ninety participants were analyzed, including 45 patients with CAP and 45 healthy controls. Pneumonia severity was assessed using the Pneumonia Severity Index (PSI) and CURB-65. Group comparisons, Spearman correlation analyses, receiver operating characteristic (ROC) analyses, and an exploratory multivariable logistic regression model were performed. Results: Presepsin concentrations were higher in patients with CAP than in healthy controls (2157 [1824–2524] vs. 1749 [1652–1879] pg/mL; p < 0.001), as were PTX3 concentrations (2.15 [1.76–2.87] vs. 1.67 [1.40–2.11] ng/mL; p < 0.001). For discrimination of CAP from healthy controls, the AUC was 0.822 (95% CI 0.728–0.902) for presepsin and 0.706 (95% CI 0.598–0.810) for PTX3. Among patients with CAP, presepsin correlated with PSI (rho = 0.552, p < 0.001) and CURB-65 (rho = 0.600, p < 0.001), while PTX3 showed stronger correlations with PSI (rho = 0.691, p < 0.001) and CURB-65 (rho = 0.668, p < 0.001). For identifying PSI classes IV–V, the AUC was 0.647 for presepsin and 0.742 for PTX3. Conclusions: Both presepsin and PTX3 were elevated in CAP and were associated with increasing disease severity. Within this pilot sample, presepsin showed a numerically higher AUC for discrimination between CAP and healthy controls, whereas PTX3 showed stronger associations with severity. Larger prospective studies are required to validate these findings.
- Open Access
- 19 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (20) , 7386
Diagnostic Value of NO-Related Biomarkers (ADMA, NO, eNOS) in Stable COPD and Acute Exacerbation of COPD
Background: Nitric oxide (NO)-related biomarkers, including asymmetric dimethylarginine (ADMA), nitric oxide (NO), and endothelial nitric oxide synthase (eNOS), may play a role in the pathophysiology and clinical progression of chronic obstructive pulmonary disease (COPD). This study aimed to investigate their diagnostic value in stable COPD and acute exacerbation. Methods: A total of 150 participants (76 females, 74 males; mean age 53.82 ± 7.06 years) were enrolled and equally distributed into control, stable COPD, and acute exacerbation groups (n = 50 each). Demographic, clinical, and laboratory parameters were compared across groups. Serum ADMA, NO, and eNOS levels were analyzed, and correlations with clinical findings were evaluated. ROC analysis was performed to determine the diagnostic performance of the biomarkers. Results: Serum ADMA levels were significantly higher in COPD patients, particularly in the acute exacerbation group (p < 0.05 for all comparisons). In contrast, NO and eNOS levels were significantly lower in COPD groups compared to controls (p < 0.05 for all comparisons). ADMA showed strong negative correlations with FEV1, FEV1/FVC, PaO2, and SaO2, whereas NO and eNOS showed positive correlations with the same parameters (all p < 0.01). For predicting acute exacerbation, an ADMA cut-off of 1.36 yielded high diagnostic accuracy (AUC = 0.983; sensitivity 86.0%; specificity 96.0%). eNOS also demonstrated predictive value (AUC = 0.823). For stable COPD, NO at a cut-off of 14.91 showed excellent diagnostic performance (AUC = 0.921). Conclusions: NO-related biomarkers, particularly ADMA and NO, may serve as reliable indicators for differentiating between stable COPD and acute exacerbation. Elevated ADMA and reduced NO and eNOS levels were closely associated with impaired lung function and oxygenation parameters. These findings suggest potential clinical utility of these biomarkers in COPD monitoring and management.
- 19 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (20) , 7386
Open AccessDiagnostic Value of NO-Related Biomarkers (ADMA, NO, eNOS) in Stable COPD and Acute Exacerbation of COPD
Background: Nitric oxide (NO)-related biomarkers, including asymmetric dimethylarginine (ADMA), nitric oxide (NO), and endothelial nitric oxide synthase (eNOS), may play a role in the pathophysiology and clinical progression of chronic obstructive pulmonary disease (COPD). This study aimed to investigate their diagnostic value in stable COPD and acute exacerbation. Methods: A total of 150 participants (76 females, 74 males; mean age 53.82 ± 7.06 years) were enrolled and equally distributed into control, stable COPD, and acute exacerbation groups (n = 50 each). Demographic, clinical, and laboratory parameters were compared across groups. Serum ADMA, NO, and eNOS levels were analyzed, and correlations with clinical findings were evaluated. ROC analysis was performed to determine the diagnostic performance of the biomarkers. Results: Serum ADMA levels were significantly higher in COPD patients, particularly in the acute exacerbation group (p < 0.05 for all comparisons). In contrast, NO and eNOS levels were significantly lower in COPD groups compared to controls (p < 0.05 for all comparisons). ADMA showed strong negative correlations with FEV1, FEV1/FVC, PaO2, and SaO2, whereas NO and eNOS showed positive correlations with the same parameters (all p < 0.01). For predicting acute exacerbation, an ADMA cut-off of 1.36 yielded high diagnostic accuracy (AUC = 0.983; sensitivity 86.0%; specificity 96.0%). eNOS also demonstrated predictive value (AUC = 0.823). For stable COPD, NO at a cut-off of 14.91 showed excellent diagnostic performance (AUC = 0.921). Conclusions: NO-related biomarkers, particularly ADMA and NO, may serve as reliable indicators for differentiating between stable COPD and acute exacerbation. Elevated ADMA and reduced NO and eNOS levels were closely associated with impaired lung function and oxygenation parameters. These findings suggest potential clinical utility of these biomarkers in COPD monitoring and management.